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Heterodimerization of the angiotensin II AT1 receptor with the receptor for the vasodepressor bradykinin,
B2R, is known to sensitize the AT1-stimulated response of hypertensive individuals in vivo. To analyze
features of that prototypic receptor heterodimer in vitro, we established a new method that uses ﬂuores-
cence resonance energy transfer (FRET) and applies for the ﬁrst time AT1-Cerulean as a FRET donor. The
Cerulean variant of the green ﬂuorescent protein as donor ﬂuorophore was fused to the C-terminus of
AT1, and the enhanced yellow ﬂuorescent protein (EYFP) as acceptor ﬂuorophore was fused to B2R. In
contrast to AT1–EGFP, the AT1-Cerulean fusion protein was retained intracellularly. To facilitate cell sur-
face delivery of AT1-Cerulean, a cleavable signal sequence was fused to the receptor’s amino terminus.
The plasma membrane-localized AT1-Cerulean resembled the native AT1 receptor regarding ligand bind-
ing and receptor activation. A high FRET efﬁciency of 24.7% between membrane-localized AT1-Cerulean
and B2R-EYFP was observed with intact, non-stimulated cells. Confocal FRET microscopy further revealed
that the AT1/B2 receptor heterodimer was functionally coupled to receptor desensitization mechanisms
because activation of the AT1-Cerulean/B2R-EYFP heterodimer with a single agonist triggered the co-
internalization of AT1/B2R. Receptor co-internalization was sensitive to inhibition of G protein-coupled
receptor kinases, GRKs, as evidenced by a GRK-speciﬁc peptide inhibitor. In agreement with efﬁcient
AT1/B2R heterodimerization, confocal FRET imaging of co-enriched receptor proteins immobilized on
agarose beads also detected a high FRET efﬁciency of 24.0%. Taken together confocal FRET imaging
revealed efﬁcient heterodimerization of co-enriched and cellular AT1/B2R, and GRK-dependent co-
internalization of the AT1/B2R heterodimer.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The angiotensin II type 1 receptor (AT1) is the major receptor
for the vasopressor angiotensin II. By regulating vascular tone, car-
diovascular function, salt and water homeostasis the AT1 receptor
exerts an indispensable physiological role. In addition to its impor-
tant physiological functions, the AT1 receptor has become one of
the major drug targets for the treatment of cardiovascular disor-
ders, which are characterized by an exaggerated AT1-stimulated
response [1,2]. Mechanisms underlying AT1 sensitization are
therefore of great importance to elucidate pathomechanisms of
diseases such as hypertension, atherosclerosis or heart failure.
Different mechanisms may contribute to an exaggerated angio-
tensin II response under pathophysiological conditions. In recent
years, receptor homo- and heterodimerization emerged as a major
mechanism controlling angiotensin II responsiveness in vivo [3–6].acology Unit, Swiss Federal
rthurerstrasse 190, CH-8057
U. Quitterer).
Y-NC-ND license.An altered dimerization of the AT1 receptor may contribute to the
angiotensin II hyperresponsiveness during the pathogenesis of car-
diovascular diseases [7–9]. For instance, covalently linked AT1
receptor dimers may contribute to the exaggerated angiotensin II
response at the onset of atherosclerosis because the covalent sta-
bilization of AT1 dimers may create a signaling platform, which
is kinetically favored to interact with the downstream signal trans-
duction cascade [7]. Covalently stabilized AT1 receptor dimers are
also a characteristic feature of preeclampsia hypertension [8]. In
preeclamptic individuals it is the covalent interaction with the bra-
dykinin B2 receptor (B2R), which accounts for the formation of a
hyperresponsive AT1 receptor platform [4,8]. A similar observation
linked AT1/B2 receptor heterodimers to the enhanced AT1 re-
sponse in renal mesangial cells of spontaneously hypertensive rats
[9]. Those examples suggest that the covalent stabilization of AT1
receptors by homo- or hetero- dimerization may facilitate receptor
signaling by creating a non-dissociable signaling platform.
Previous studies mainly focused on AT1 dimerization under
in vivo conditions. In view of the pathophysiological role,
transfected cell systems are of increasing interest to facilitate
the study of mechanisms underlying the formation of AT1
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transfer (FRET) is a versatile technology for the analysis of protein
interactions such as receptor homo- and heterodimerization
[12,13]. FRET is capable to detect interactions between donor and
acceptor ﬂuorophores in close proximity occurring in the range
of 1–10 nm in distance [12,13]. Therefore we applied FRET for
the analysis of AT1/B2R heterodimerization. As FRET donor, the
Cerulean variant of the enhanced green ﬂuorescent protein was
chosen and fused to the carboxyl terminus of AT1 (AT1-Cerulean)
because Cerulean is 2.5-fold brighter than the cognate ECFP and
yields a substantially improved signal-to-noise-ratio in FRET mea-
surements [14]. As FRET acceptor, the enhanced yellow ﬂuorescent
protein was fused to the carboxyl terminus of the bradykinin B2
receptor (B2R-EYFP). With a high FRET efﬁciency of more than
24%, confocal FRET imaging revealed the close interaction between
membrane-localized AT1-Cerulean and B2R-EYFP indicative of efﬁ-
cient heterodimerization of AT1/B2 receptors.2. Materials and methods
2.1. Cell culture and cell transfection
Human embryonic kidney cells (HEK293) were cultivated and
transfected with plasmids encoding AT1-Cerulean and B2R-EYFP
as described [4]. Overlapping PCR was performed to create cDNAs
encoding AT1-Cerulean and B2R-EYFP, i.e. the cDNA of Cerulean
[14] and EYFP was fused with a linker (GlyGlyGlyGlyGly) in frame
to the C-terminus of AGTR1 (amino acid 359) and BDKRB2 (amino
acid 391), respectively. To enhance the membrane localization of
AT1-Cerulean, the cleavable signal sequence of inﬂuenza hemag-
glutinin (MKTIIALSYIFCLVFA; h-sp; [15]) was added by PCR to
the N-terminus of AT1-Cerulean to create (h-sp)AT1-Cerulean.
Analogously, the signal sequence of the secreted protein resistin
(MKALCLLLLPVLGLLVSS; r-sp) was fused to the N-terminus of
AT1-Cerulean to create (r-sp)AT1-Cerulean. The identity of all
DNA constructs was veriﬁed by DNA sequencing. Cellular inositol
phosphate levels were quantiﬁed as described [4]. For receptor
internalization, cells co-expressing (h-sp)AT1-Cerulean/B2R-EYFP
were stimulated with angiotensin II (2 lM) for 40 min at 37 C.
To inhibit G-protein-coupled receptor kinases (GRKs), a GRK-spe-
ciﬁc peptide inhibitor was expressed [16]. Radioligand binding
afﬁnities were determined with membranes of transiently trans-
fected HEK293 cells in the presence of protease inhibitors with
50 lg protein/point for 1 h at 22 C. Saturation isotherms were
determined by incubating membranes with varying concentrations
of Sar1,[125I]Tyr4,Ile8-angiotensin II (2200 Ci/mmol; Perkin Elmer)
or [2,3,-prolyl-3,4-3H]bradykinin (96 Ci/mmol; Perkin Elmer). Non-
speciﬁc binding was determined by the addition of 1 lM unlabeled
angiotensin II or bradykinin for AT1 or B2 receptors, respectively
[8].2.2. Co-immunoenrichment studies
Co-immunoenrichment of B2R-EYFP and (h-sp)AT1-Cerulean
was performed with solubilized membranes of HEK293 cells
expressing B2R-EYFP and/or (h-sp)AT1-Cerulean, similarly as de-
scribed [10,11,17]. For visualization of (co-)enriched receptor pro-
teins by confocal FRET imaging, membranes (prepared from
3  107 cells) were solubilized with PBS containing 1% sodium
deoxycholate, 0.01% Tween 20, and protease inhibitors. The solu-
bilisate was diluted 1:10 (with PBS supplemented with 1% with bo-
vine serum albumin and 0.01% Tween 20), and applied to ProteinA
sepharose loaded with B2R-speciﬁc antibodies or control antibod-
ies. After overnight incubation at 4 C and three washing steps
(with PBS containing 0.01% Tween 20), ProteinA sepharose beadswere imaged by confocal FRET microscopy. The following antibod-
ies were used for immunoblotting and/or immuno-enrichment:
afﬁnity-puriﬁed B2R-speciﬁc antibodies raised in rabbit/rat against
an antigen encompassing amino acids 356–391 of the human B2R
sequence, and afﬁnity-puriﬁed AT1-speciﬁc antibodies raised in
rabbit/rat against an antigen encompassing amino acids 306–359
of the human AT1R sequence [10,11].
2.3. Confocal FRET Imaging
Confocal FRET imaging of HEK cells co-expressing membrane-
localized AT1-Cerulean and B2R-EYFP was performed with a confo-
cal laser-scanning microscope (SP5-CLSM, Leica) similarly as
described [13]. Cerulean was excited using the 458 nm line of the
argon laser at moderate laser power, and emission was detected
at 470–485 nm. EYFP was excited at 495 nm, and emission was de-
tected at 520–535 nm. After image collection, EYFP was bleached
at 514 nm at 100% laser power. Quantiﬁcation of donor and accep-
tor ﬂuorescence emission intensities at 470–485 nm and 520–
535 nm before and after photobleaching of a selected region of
interest was used to calculate FRET efﬁciencies. Calculation of the
FRET efﬁciency (EF) was performed with the FRET-ABWizard (Leica
Application Suite Advanced Fluorescence Version 2.3.6) according
to the formula EF=(Iafter  Ibefore)  100/Iafter, where Iafter is the Ceru-
lean intensity after the EYFP bleach and Ibefore is the Cerulean
intensity before the EYFP bleach. The formula yields the increase
in Cerulean ﬂuorescence induced by the EYFP bleach normalized
by the Cerulean ﬂuorescence after the bleach [13]. Confocal FRET
imaging of enriched receptors immobilized on sepharose beads
was performed essentially as described for cellular receptors ex-
pressed in HEK cells.
2.4. Statistical analyses
Unless otherwise stated, data are expressed as mean ± S.D. To
determine signiﬁcance between two groups, comparisons were
made using the unpaired two-tailed Student’s t test, p values of
<0.05 were considered signiﬁcant.3. Results
3.1. A cleavable signal peptide facilitates cell surface delivery of AT1-
Cerulean
In view of the physiological importance of AT1/B2R heterodi-
mers in vivo [8,9], we sought to establish a FRET-based method
to analyze features of AT1/B2R heterodimers in vitro. For FRET
studies we chose the Cerulean variant of the enhanced green ﬂuo-
rescent protein, which is a highly efﬁcient FRET donor [14]. In con-
trast to AT1–EGFP, fusion of Cerulean to the C-terminus of AT1
induced the predominant intracellular retention of AT1-Cerulean
(Fig. 1A).
To increase the cell surface delivery of AT1-Cerulean, the cleav-
able signal peptide of the inﬂuenza hemagglutinin (h-sp) was fused
to the N-terminus of the receptor. The cleavable signal peptide sig-
niﬁcantly enhanced the cell surface delivery of (h-sp)AT1-Cerulean
as determined by radioligand binding (Fig. 1B). Fluorescence
microscopy revealed the plasma membrane localization of (h-
sp)AT1-Cerulean and the co-localization with B2R-EYFP (Fig. 1C).
A similar enhancement of plasma membrane localization of AT1-
Cerulean was achieved with the signal peptide of the mammalian
secreted protein, resistin, as visualized with (r-sp)AT1-Cerulean-
expressing cells (Fig. 1D). As a control, ligand afﬁnity and activa-
tion of membrane-localized AT1-Cerulean and B2R-EYFP receptors
were comparable to the wild-type AT1 and B2 receptor, respec-
Fig. 1. A cleavable signal peptide facilitates cell surface delivery of AT1-Cerulean.
(A) Representative ﬂuorescence microscopy images of transfected HEK cells show
the intracellular retention of AT1-Cerulean without signal peptide whereas AT1–
EGFP was predominantly membrane-localized (right vs. left panel). (B) Quantiﬁca-
tion of cell surface AT1–EGFP, AT1-Cerulean (AT1-Cer) and (h-sp)AT1-Cerulean
(with cleavable signal peptide) by radioligand binding after transfection of HEK
cells with comparable amounts of plasmid DNA. Data represent mean ± S.D., n = 3
independent experiments, ⁄p < 0.01 (h-sp-AT1-Cer vs. AT1-Cer). (C and D) Fluores-
cence microscopy showed the co-localization of membrane-localized AT1-Cerulean
and B2R-EYFP. Plasma membrane localization of AT1-Cerulean was facilitated by N-
terminal fusion of the signal peptide of the inﬂuenza hemagglutinin in (h-sp)AT1-
Cerulean (C), and the signal peptide of resistin in (r-sp)AT1-Cerulean (D). The
middle panels show ﬂuorescence microscopy images of B2R-EYFP, and the right
panels present overlay images. Fluorescence microscopy images are representative
of at least 4 independent experiments (bar 10 lm; A, C, D). (E and F) Binding
constants (Kd) of AT1, (h-sp)AT1-Cerulean and (r-sp)AT1-Cerulean for Sar1,
[125I]Tyr4,Ile8-angiotensin II (E; [125I]Sar1,Ile8angiotensin II), and of B2R and B2R-
EYFP for [2,3,-prolyl-3,4-3H]bradykinin (F; [3H]bradykinin) were determined by
saturation binding experiments with membranes of transfected HEK cells. The
concentration of agonist required to induce half maximum stimulation of cellular
inositol phosphate levels (EC50) was determined for the angiotensin II-stimulated
(E) and bradykinin-stimulated (F) inositol phosphate signal with increasing
concentrations of agonist (0.1 nM–1 lM) with transfected HEK cells expressing
comparable levels of the indicated receptor. Data represent mean ± S.D., n = 3
independent experiments.
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peptides facilitated cell surface delivery of AT1-Cerulean. Uponenhancement of cell surface delivery, the plasma membrane local-
ized AT1-Cerulean was co-localized with B2R-EYFP.
3.2. Co-enrichment of the AT1-Cerulean/B2R-EYFP receptor complex
We assessed the interaction between AT1-Cerulean and B2R-
EYFP by co-enrichment with receptor-speciﬁc antibodies. Afﬁn-
ity-puriﬁed AT1-speciﬁc antibodies speciﬁcally cross-reacted with
the wild-type AT1 receptor of 73 ± 4 kDa and the (h-sp)AT1-Ceru-
lean protein of 102 ± 8 kDa (Fig. 2, lanes 1 and 2) whereas B2R-spe-
ciﬁc antibodies cross-reacted with the wild-type B2R of 74 ± 5 kDa
and the B2R-EYFP protein of 104 ± 8 kDa (Fig. 2, lanes 6, 7). The
apparent molecular mass of wild-type AT1 and B2R was in good
agreement with previous results [10,11,18]. To determine the pro-
tein complex formation between co-expressed (h-sp)AT1-Cerulean
and B2R-EYFP, AT1-Cerulean was immunoafﬁnity-enriched from
solubilized membranes with anti-AT1 antibodies, which were
covalently coupled to Afﬁgel-10. The enriched AT1-Cerulean pro-
tein of 102 kDa was detected in immunoblot with AT1-speciﬁc
antibodies (Fig. 2, lane 3). Immunoblot analysis of enriched pro-
teins showed that AT1-speciﬁc antibodies co-enriched signiﬁcant
amounts of B2R-EYFP as detected in immunoblot with anti-B2R
antibodies (Fig. 2, lane 9). The reciprocal experiment gave similar
results. Upon enrichment of B2R-EYFP with a B2R-speciﬁc afﬁnity
matrix followed by detection with anti-B2R antibodies in immuno-
blot (Fig. 2, lane 8), signiﬁcant amounts of AT1-Cerulean were co-
enriched together with B2R-EYFP as revealed by probing of the
immunoblot with anti-AT1 antibodies (Fig. 2, lane 4). As a speciﬁc-
ity control, membranes of cells expressing each receptor individu-
ally were mixed prior to the incubation with the AT1-afﬁnity
matrix or the B2R-afﬁnity matrix. Immunoblot detection showed
that the B2R-speciﬁc afﬁnity matrix did not co-enrich AT1-Ceru-
lean from a mix of membranes prepared from cells expressing
AT1-Cerulean and B2R-EYFP in different cells (Fig. 2, lane 5). Anal-
ogously, the AT1-speciﬁc afﬁnity matrix did not co-enrich B2R
without co-expression of AT1 in the same cell (Fig. 2, lane 10). Ta-
ken together, the co-enrichment experiments strongly suggest that
AT1-Cerulean and B2R-EYFP form a protein complex when co-ex-
pressed in the same cell similarly as the wild-type AT1 and B2
receptor [4,8,10,11].
3.3. Receptor heterodimerization between co-enriched AT1-Cerulean
and B2R-EYFP receptor proteins
To simplify the detection of (co-)enriched receptors we per-
formed receptor enrichment with receptor-speciﬁc antibodies
immobilized on ProteinA sepharose, and directly analyzed the Pro-
teinA sepharose beads by ﬂuorescence microscopy (Fig. 3A). Fluo-
rescence microscopy showed that the anti-B2R-ProteinA sepharose
enriched B2R-EYFP as visible by the yellow ﬂuorescence of the aga-
rose beads (Fig. 3A, left panel). Concomitantly, (h-sp)AT1-Cerulean
was co-enriched with B2R (Fig. 3A, middle panel). The right panel
shows the overlay of B2R-EYFP/AT1-Cerulean ﬂuorescence images
(Fig. 3A, right panel). As a control, we used ProteinA sepharose
loaded with unrelated control IgG (Fig. 3B). ProteinA sepharose
with control IgG did neither enrich B2R-EYFP nor AT1-Cerulean
(Fig. 3B). These experiments conﬁrmed the protein complex forma-
tion between AT1-Cerulean and B2R-EYFP. The direct identiﬁcation
of enriched (ﬂuorescent) proteins by ﬂuorescence microscopy
greatly facilitated the visualization of protein complexes by
bypassing the immunoblot identiﬁcation step of enriched/co-en-
riched proteins.
We analyzed whether co-enriched AT1-Cerulean/B2R-EYFP pro-
teins formed heterodimers. FRET is a versatile method capable to
identify protein interactions in close proximity occurring in the
range of 1–10 nm in distance. We used confocal FRET imaging to
Fig. 2. Co-enrichment of the membrane-localized AT1-Cerulean/B2R-EYFP receptor complex. Immunoblot detection of wild-type AT1 (lane 1) or membrane-localized
(h-sp)AT1-Cerulean (AT1-Cer; lane 2) with afﬁnity-puriﬁed anti-AT1 antibodies (IB: anti-AT1), and wild-type B2R (lane 6) or B2R-EYFP (lane 7) with anti-B2R antibodies (IB:
anti-B2) on membranes of receptor-expressing HEK cells. Immunoafﬁnity enrichment (AP) of the membrane-localized AT1-Cerulean with an anti-AT1 afﬁnity matrix (AP:
AT1) from solubilized membranes of cells expressing (h-sp)AT1-Cerulean alone (lane 3), (h-sp)AT1-Cerulean together with B2R-EYFP (lane 9), or from a solubilized membrane
mixture prepared from cells expressing (h-sp)AT1-Cerulean and B2R-EYFP in different cells (lane 10). The enriched AT1-Cerulean protein was detected in immunoblot (IB)
with anti-AT1 antibodies (lane 3; IB: anti-AT1), and co-enriched proteins were probed for B2R-EYFP with anti-B2R antibodies in immunoblot (lanes 9, 10; IB: anti-B2). The
B2R-EYFP protein was immuno-afﬁnity enriched with an anti-B2R afﬁnity matrix (AP: B2) from solubilized membranes of cells co-expressing B2R-EYFP with h-spAT1-
Cerulean (lane 4), from a solubilized membrane mix prepared from cells expressing B2R-EYFP and h-spAT1-Cerulean in different cells (lane 5), or from solubilized membranes
of cells expressing B2R-EYFP alone (lane 8). Immunoaffﬁnity-enriched proteins were probed for co-enriched AT1-Cerulean with anti-AT1 antibodies (IB: anti-AT1) in
immunoblot (lanes 4, 5), and enriched B2R-EYFP was identiﬁed in immunoblot with anti-B2R antibodies (lane 8; IB: anti-B2).
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EYFP receptor proteins. FRET efﬁciencies were quantiﬁed by DFRAP
(donor ﬂuorescence recovery after photo-bleaching) experiments.
With this approach, the yellow acceptor ﬂuorophore, B2R-EYFP,
was photo-bleached by over-excitation at 514 nm (Fig. 3C, middle
vs. left panel). After acceptor photo-bleaching of B2R-EYFP,
unquenching of the ﬂuorescence donor, AT1-Cerulean, was ob-
served (Fig. 3C). Quantitative data evaluation showed a high FRET
efﬁciency of 24.0 ± 3.0% (n = 5; ±S.E.M.) between co-enriched AT1-
Cerulean/B2R-EYFP, indicative of receptor heterodimerization.
These experiments show that the established FRET method is capa-
ble to visualize heterodimerization of co-enriched receptors.3.4. Confocal FRET imaging demonstrates heterodimerization and co-
internalization of membrane-localized AT1-Cerulean/B2R-EYFP
We next asked whether confocal FRET imaging also detected
AT1/B2R heterodimers of intact cells. Image acquisition before
and after bleaching conﬁrmed the photobleaching of B2R-EYFP
(Fig. 4A, middle vs. left panel). Similarly as described above,
un-quenching of the ﬂuorescence intensity of the FRET donor,
AT1-Cerulean, after acceptor bleaching, was used to calculate FRET
efﬁciencies (Fig. 4A, right panel). Quantitative evaluation of DFRAP
experiments revealed a high FRET efﬁciency of 24.7 ± 1.8% (n = 11,
±S.E.M.) between membrane-localized (h-sp)AT1-Cerulean and
B2R-EYFP (Fig. 4A and D). These experiments show a close protein
interaction between plasma membrane-localized AT1-Cerulean
and B2R-EYFP, indicative of AT1/B2 receptor heterodimerization.
FRET efﬁciencies of co-enriched and cellular AT1/B2R were compa-
rable (cf. Fig. 3C), indicating a high stability of AT1/B2R
heterodimers.
Receptor heterodimerization is accompanied by receptor
co-internalization [6,19]. To analyze whether the AT1-Cerulean/
B2R-EYFP was functionally coupled to receptor desensitization
mechanisms of HEK cells, we stimulated cells with angiotensin II.
Confocal FRET microscopy revealed that angiotensin II (2 lM) in-
duced the co-internalization of AT1-Cerulean/B2R-EYFP without
signiﬁcantly decreasing the FRET efﬁciency (Fig. 4B and D). Radio-
ligand binding was used to quantify the co-internalization of AT1/
B2R heterodimers. Stimulation with angiotensin II (2 lM) signiﬁ-
cantly decreased the number of plasma membrane localized B2R
by 37 ± 3% (Fig. 4E). As a control, angiotensin II had no effect on
the number of plasma membrane-localized B2R in the absence ofAT1 (data not shown). Vice versa, stimulation with bradykinin
(2 lM) induced the co-internalization of plasma membrane local-
ized AT1 by 45 ± 4% (Fig. 4F). Thus, confocal FRET imaging and radi-
oligand binding detected the co-internalization of the AT1/B2R
heterodimer upon stimulation with a single agonist. The extent
of receptor co-internalization of the AT1/B2R heterodimer as deter-
mined by radioligand binding was in good agreement with previ-
ous studies on co-internalization of the AT1/b-adrenergic
receptor heterodimer [6].
Desensitization and internalization of AT1 or B2 receptors is
mediated by G-protein-coupled receptor kinases, GRKs [18,20].
We asked whether co-internalization of the AT1/B2R heterodimer
was also mediated by GRKs and expressed a GRK-speciﬁc peptide
inhibitor [16]. Confocal FRET microscopy demonstrated that the
angiotensin II-stimulated co-internalization of AT1-Cerulean/B2R-
EYFP heterodimers was signiﬁcantly reduced upon expression of
the GRK-speciﬁc inhibitor (Fig. 4C and D). Radioligand binding con-
ﬁrmed that co-internalization of the AT1/B2R heterodimer was
inhibited by the GRK-speciﬁc inhibitor (Fig. 4E and F). Taken to-
gether, our experiments provide strong evidence that stimulation
of AT1/B2 receptor heterodimers with a single agonist induces
receptor co-internalization, which is largely dependent on GRKs.4. Discussion
Sensitization of the angiotensin II-mediated response is a char-
acteristic feature of cardiovascular diseases [1,2]. Heterodimeriza-
tion between the AT1 and B2R is known to contribute to the
angiotensin II hypersensitivity of hypertensive individuals in vivo
[8,9]. In view of the pathophysiological importance, mechanisms
underlying the formation of AT1/B2 receptor heterodimers are of
major interest [10,11]. To delineate mechanisms accounting for
AT1/B2R heterodimerization in vitro, the current study established
a new method that monitors AT1/B2R heterodimerization by con-
focal FRET imaging and applies for the ﬁrst time AT1-Cerulean as a
FRET donor. The established system revealed that proper cell sur-
face delivery and membrane localization was a prerequisite for
efﬁcient AT1/B2R heterodimerization. A high FRET efﬁciency be-
tween AT1-Cerulean as FRET donor and B2R-EYFP as FRET acceptor
of more than 24% was observed when plasma membrane localiza-
tion of AT1-Cerulean was enhanced by a cleavable signal peptide.
AT1-Cerulean/B2R-EYFP heterodimers were functionally coupled
Fig. 3. Receptor heterodimerization between co-enriched AT1-Cerulean and B2R-
EYFP receptor proteins. (A) Immunoenrichment of B2R-EYFP with anti-B2R-
ProteinA sepharose from solubilized membranes of HEK cells co-expressing B2R-
EYFP and membrane-localized (h-sp)AT1-Cerulean. Enriched B2R-EYFP (left) and
co-enriched AT1-Cerulean (middle) immobilized on sepharose beads were visual-
ized by ﬂuorescence microscopy (bar 50 lm). The right panel is an overlay of B2R-
EYFP/AT1-Cerulean ﬂuorescence images. (B) As a control, immunoenrichment was
performed with ProteinA sepharose loaded with control IgG. (C) Confocal FRET
imaging revealed a high FRET efﬁciency of 24.0 ± 3.0% (n = 5; ±S.E.M.) between
enriched B2R-EYFP and co-enriched (h-sp)AT1-Cerulean. Overlay images before
(pre-bleach, left) and after (post-bleach, middle) photo-bleaching of the acceptor
B2R-EYFP are shown (bar 25 lm). The right panel visualizes calculated FRET
efﬁciencies (%) in pseudo-color (max-red/min-blue). All data (A–C) are represen-
tative of 3–5 independent experiments.
Fig. 4. Confocal FRET imaging demonstrates heterodimerization and co-internali-
zation of membrane-localized AT1-Cerulean and B2R-EYFP. (A–C) Fluorescence
intensity images were sequentially collected before (left; pre-bleach) and after
(middle; post-bleach) photo-bleaching of the acceptor B2R-EYFP at 514 nm. The
right panels visualize calculated FRET efﬁciencies (%) in pseudo-color (max-red/
min-blue). Images were taken from cells co-expressing membrane-localized (h-
sp)AT1-Cerulean and B2R-EYFP (bar: 10 lm). (B and C) Co-internalization of AT1-
Cerulean/B2R-EYFP was induced with angiotensin II (+AngII; 2 lM, 40 min, 37 C).
(C) Co-expression of a GRK-speciﬁc inhibitor (+GRK-Inhib) signiﬁcantly reduced
receptor co-internalization. (D) Calculated FRET efﬁciencies of independent exper-
iments (n = 8–11; ±S.E.M.). (E and F) Number of cell surface receptors were
quantiﬁed by radioligand binding. Co-internalization of (h-sp)AT1-Cerulean/B2R-
EYFP was induced by incubation with angiotensin II (Ang II) or bradykinin (Bk)
applied at a concentration of 2 lM for 40 min at 37 C. Data represent mean ± -
S.E.M., n = 3 (⁄p < 0.01, +agonist vs. cont.).
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dependent co-internalization of AT1/B2R heterodimers.
The protein complex formation between membrane-localized
AT1-Cerulean and B2R-EYFP was also veriﬁed by co-immunoen-
richment with receptor-speciﬁc antibodies. In addition to conven-
tional receptor immuno-afﬁnity enrichment/co-enrichment and
immunoblot identiﬁcation of enriched proteins, we visualized the
enriched protein complex of AT1-Cerulean/B2R-EYFP directly by
confocal microscopy of ProteinA sepharose beads immobilizing im-
muno-enriched proteins. That approach facilitated the detection of
protein interactions between ﬂuorescent protein-tagged receptors
by bypassing the immunoblot identiﬁcation step. Moreover, the
method enabled the quantiﬁcation of receptor heterodimerization
between co-enriched proteins by confocal FRET imaging. Puriﬁed
and cellular AT1-Cerulean/B2R-EYFP heterodimers displayed a
comparable FRET efﬁciency of 24% indicating a high stability
AT1/B2R heterodimers.
AT1/B2R is a prototypic GPCR heterodimer and displays many
features, which were similarly observed with other GPCR heterodi-
mers, for instance disulﬁde linkage [4,8,21], altered signal sensiti-zation [4,19] and co-internalization [6,11,19]. Therefore the
established method could be useful to study features of other G-
protein-coupled receptor heterodimers as well. Taken together,
we have established a new method that enables the detection of
AT1/B2R heterodimerization in vitro by confocal FRET imaging.
The method relies on a cleavable signal peptide, which improves
plasmamembrane localization and cell surface delivery of the FRET
donor, AT1-Cerulean.
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